Skip to main content
Figure 3 | BMC Veterinary Research

Figure 3

From: GS-9219/VDC-1101 - a prodrug of the acyclic nucleotide PMEG has antitumor activity inspontaneous canine multiple myeloma

Figure 3

Bone marrow cytologic and molecular complete response in a dog with spontaneous myeloma receiving VDC-1101 monotherapy. The photomicrographs above represent pre-treatment (A) and post-treatment (B) bone marrow cytology from an 8 year old male castrated Labrador retriever with melphalan-refractory myeloma. The pre-treatment sample contained 30% atypical plasma cells, whereas the post-treatment sample contained 2% morphologically normal plasma cells. PCR for antigen receptor rearrangement was performed on bone marrow obtained from this patient prior to and following VDC-1101 (C). 1: Positive control for amplifiable DNA. 2,3: PCR products generated employing 2 distinct sets of immunoglobulin gene primers. 4: PCR products generated employing primers for T cell receptor gene. A solitary band, indicating a monoclonal immunoglobulin gene rearrangement, is present in Lane 2 of the pre-treatment sample. This is replaced with polyclonal immunoglobuin gene rearrangements in Lane 2 of the post-treatment sample, indicating disappearance of the malignant clone.

Back to article page